These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 27276999)

  • 21. A naturalistic on-off-on trial of dextromethorphan/quinidine for agitation associated with cerebellar injury.
    Daly JP; Caplan JP
    Psychosomatics; 2012; 53(5):470-3. PubMed ID: 22458990
    [No Abstract]   [Full Text] [Related]  

  • 22. AVP-923, a combination of dextromethorphan hydrobromide and quinidine sulfate for the treatment of pseudobulbar affect and neuropathic pain.
    Olney N; Rosen H
    IDrugs; 2010 Apr; 13(4):254-65. PubMed ID: 20373255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dextromethorphan and quinidine in adult patients with uncontrolled painful diabetic peripheral neuropathy: a 29-day, multicenter, open-label, dose-escalation study.
    Thisted RA; Klaff L; Schwartz SL; Wymer JP; Culligan NW; Gerard G; Pope LE; Berg JE
    Clin Ther; 2006 Oct; 28(10):1607-18. PubMed ID: 17157116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of one-year dextromethorphan/quinidine treatment on management of respiratory impairment in amyotrophic lateral sclerosis.
    Sancho J; Ferrer S; Burés E; Luis Díaz J; Torrecilla T; Signes-Costa J; Servera E
    Respir Med; 2021 Sep; 186():106536. PubMed ID: 34260979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of pseudobulbar affect in ALS.
    Smith RA; Brooks BR
    Lancet Neurol; 2005 May; 4(5):270. PubMed ID: 15847840
    [No Abstract]   [Full Text] [Related]  

  • 26. Pseudobulbar affect in multiple sclerosis: toward the development of innovative therapeutic strategies.
    Miller A
    J Neurol Sci; 2006 Jun; 245(1-2):153-9. PubMed ID: 16674978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Additional evidence for a therapeutic effect of dextromethorphan/quinidine on bulbar motor function in patients with amyotrophic lateral sclerosis: A quantitative speech analysis.
    Green JR; Allison KM; Cordella C; Richburg BD; Pattee GL; Berry JD; Macklin EA; Pioro EP; Smith RA
    Br J Clin Pharmacol; 2018 Dec; 84(12):2849-2856. PubMed ID: 30152872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of pseudobulbar affect (PBA) in a patient with a history of traumatic brain injury, partial brain resection, and brainstem stroke: a case report.
    Young FG; Nguyen D
    J Med Case Rep; 2020 Dec; 14(1):235. PubMed ID: 33272325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PRISM: a novel research tool to assess the prevalence of pseudobulbar affect symptoms across neurological conditions.
    Brooks BR; Crumpacker D; Fellus J; Kantor D; Kaye RE
    PLoS One; 2013; 8(8):e72232. PubMed ID: 23991068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers.
    Schoedel KA; Pope LE; Sellers EM
    Clin Drug Investig; 2012 Mar; 32(3):157-69. PubMed ID: 22283559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of pseudobulbar affect symptoms in the nursing home setting: Development and assessment of a screening tool.
    Allen C; Zarowitz B; O'Shea T; Peterson E; Yonan C; Waterman F
    Geriatr Nurs; 2018; 39(1):54-59. PubMed ID: 28807457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments.
    Miller A; Pratt H; Schiffer RB
    Expert Rev Neurother; 2011 Jul; 11(7):1077-88. PubMed ID: 21539437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect.
    Pioro EP; Brooks BR; Cummings J; Schiffer R; Thisted RA; Wynn D; Hepner A; Kaye R;
    Ann Neurol; 2010 Nov; 68(5):693-702. PubMed ID: 20839238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pseudobulbar affect: an under-recognized and under-treated neurological disorder.
    Work SS; Colamonico JA; Bradley WG; Kaye RE
    Adv Ther; 2011 Jul; 28(7):586-601. PubMed ID: 21660634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NueDexta: A Treatment for Pseudobulbar Affect.
    Roman MW
    Issues Ment Health Nurs; 2015; 36(12):1019-21. PubMed ID: 26735510
    [No Abstract]   [Full Text] [Related]  

  • 36. Therapeutic Approach of a High Functioning Individual With Traumatic Brain Injury and Subsequent Emotional Volatility With Features of Pathological Laughter and Crying With Dextromethorphan/Quinidine.
    Garcia-Baran D; Johnson TM; Wagner J; Shen J; Geers M
    Medicine (Baltimore); 2016 Mar; 95(12):e2886. PubMed ID: 27015166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dextromethorphan/quinidine (Nuedexta) for pseudobulbar affect.
    Med Lett Drugs Ther; 2011 Jun; 53(1366):46-7. PubMed ID: 21659969
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy and safety of dextromethorphan/quinidine at two dosage levels for diabetic neuropathic pain: a double-blind, placebo-controlled, multicenter study.
    Shaibani AI; Pope LE; Thisted R; Hepner A
    Pain Med; 2012 Feb; 13(2):243-54. PubMed ID: 22314263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacotherapy for the Pseudobulbar Affect in Individuals Who Have Sustained a Traumatic Brain Injury: a Systematic Review.
    Hicks AJ; Clay FJ; Ponsford JL; Perry LA; Jayaram M; Batty R; Hopwood M
    Neuropsychol Rev; 2020 Mar; 30(1):28-50. PubMed ID: 31942705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current concepts in the pharmacotherapy of pseudobulbar affect.
    Pioro EP
    Drugs; 2011 Jun; 71(9):1193-207. PubMed ID: 21711063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.